Biomarker Assay Development, Qualification, and Validation
暂无分享,去创建一个
Shuguang Huang | Cheng Su | Guang Chen | Winnie Weng | Shuguang Huang | W. Weng | Cheng Su | Guang Chen
[1] Viswanath Devanarayan,et al. Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.
[2] Shobha Purushothama,et al. Parallelism: considerations for the development, validation and implementation of PK and biomarker ligand-binding assays. , 2014, Bioanalysis.
[3] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[4] H. Soares,et al. Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference Report , 2005, Pharmaceutical Research.
[5] Binodh DeSilva,et al. Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.
[6] Douglas Chesher,et al. Evaluating assay precision. , 2008, The Clinical biochemist. Reviews.
[7] S. Piccoli,et al. Biomarker assay validation. , 2018, Bioanalysis.
[8] Jean W. Lee,et al. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[9] Patrick Bennett,et al. Parallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: pros and cons. , 2017, Bioanalysis.
[10] Kiyoshi Ichihara,et al. An appraisal of statistical procedures used in derivation of reference intervals , 2010, Clinical chemistry and laboratory medicine.